Sanofi
Biopharmaceuticals · France
Sanofi discovers, makes and sells prescription medicines and vaccines, led by the immunology drug Dupixent.
What makes it different
A third of sales come from one medicine shared with Regeneron.
36.0%Of net sales from DupixentFY2025
Dupixent was developed with Regeneron, so a large part of its profit goes to the partner.
How big it is
How big is Sanofi?
€43.6BNet salesFY2025
74,846EmployeesFY2025
2BUnits soldFY2025
How it makes money FY2025
Dupixent and vaccines carry most of the sales.
- Dupixent36%€15.7B
- Vaccines18%€7.9B
- All other medicines46%€20.0B
How the business works
Immunology blockbuster funds rare diseases and vaccines.
- 1Patented immunology and rare-disease drugs
- 2Vaccines and insulins worldwide
- 3Partner and acquire new programmes
Dupixent is more than a third of net sales, so Sanofi pays partners and buys companies to widen the base.
Who owns it
- L'Oréal7.27%
- BlackRock, Inc.7.09%
- Employees2.92%
CEO: Belén Garijo
Who it competes with
Key moments
- 1973Founded by Elf Aquitaine
- 1994Buys Sterling Winthrop prescription business
- 4-08Takes control of Aventis
- 1-04Acquires Genzyme
- 7-03FDA approves Dupixent
Sources
Every number on this page comes from Sanofi's own reports.
Full profile
The rest of the story is in the app.
What Sanofi tracks22 metrics
Phase 3 projects in development
Employees
Patients treated by the Global Health Unit
Results, quarter by quarterwith a chart
Revenue
Profit
Margin
Where the money comes from3 regions
United States
Europe
Rest of the World
The full timeline16 moments
2022
2025
2026
Sanofi vs Pfizerside by side
Revenue
Profit
People
Point your phone at a logo.
See the company behind it.
The full story in 12 chapters · compare any two companies · 335 companies, and any other on request.
Download on the App Store
